Table 1.

Relationship between galectin-3 and CD34 expression and clinicopatholo gical features of 165 patients with hepatocellular carcinoma

Clinicopathologic variable	N	Galectin-3 expression		P	Microvessel counts of CD34	Range of CD34	P
		Low	High
All cases	165	30 (18.2%)	135 (81.8%)		35.80 ± 20.82	0-77
Age (years)				0.146			0.952
<50	93	20 (21.5%)	73 (78.5%)		34.64 ± 20.83	1-77
≥50	72	10 (13.9%)	62 (86.1%)		37.28 ± 20.85	0-76
Sex				0.353			0.926
Male	133	23 (17.3%)	110 (82.7%)		36.63 ± 20.72	0-77
Female	32	7 (21.9%)	25 (78.1%)		32.33 ± 21.21	1-74
Tumor size(cm)				0.393			0.103
<5	67	11 (16.4%)	56 (83.6%)		37.50 ± 19.45	0-77
≥5	98	19 (19.4%)	79 (80.6%)		34.63 ± 21.72	2-76
Histological differentiation				0.993			0.217
Good	41	7 (17.1%)	34 (82.9%)		39.89 ± 21.51	3-77
Moderate	95	17 (17.9%)	78 (82.1%)		33.43 ± 19.48	0-75
Poor	29	6 (20.7%)	23 (79.3%)		37.74 ± 24.05	7-76
Liver cirrhosis				0.361			0.621
No	27	6 (22.2%)	21 (77.8%)		37.86 ± 21.43	11-77
Yes	138	24 (17.4%)	114 (82.6%)		35.39 ± 20.75	0-76
HBsAg				0.627			0.139
Negative	17	3 (17.6%)	14 (82.4%)		30.61 ± 18.38	1-76
Positive	148	27 (18.2%)	121 (81.8%)		36.39 ± 21.06	0-77
Serum alpha fetoprotein				<0.01			0.843
<25 μg/L	47	20 (42.6%)	27 (57.4%)		39.61 ± 20.62	0-77
≥25 μg/L	118	10 (8.5%)	108 (91.5%)		34.27 ± 20.79	1-76
Distant metastasis				0.128			0.252
No	152	30 (19.7%)	122 (80.2%)		35.38 ± 20.55	0-77
Yes	13	0 (0%)	13 (100%)		40.60 ± 24.15	10-76
Presence of intrahepatic metastasis				0.254			0.82
No	138	23 (16.7%)	115 (83.3%)		34.97 ± 20.73	0-77
Yes	27	7 (25.9%)	20 (74.1%)		40.03 ± 21.14	3-75
Recurrence				0.999			0.256
No	154	28 (18.2%)	126 (81.8%)		35.62 ± 20.53	0-77
Yes	11	2 (18.2%)	9 (81.8%)		38.21 ± 25.54	3-76